Altimmune (ALT) Non-Current Deffered Revenue (2010 - 2018)

Altimmune (ALT) has 5 years of Non-Current Deffered Revenue data on file, last reported at $1.0 million in Q4 2018.

• On a quarterly basis, Non-Current Deffered Revenue rose 170.59% year-over-year to $1.0 million in Q4 2018; TTM through Dec 2018 was $1.0 million, a 170.59% increase from a year earlier, with the FY2018 full-year figure at $1.0 million, up 170.59% from the prior year.
• Non-Current Deffered Revenue for Q4 2018 stood at $1.0 million, down from $1.1 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for ALT reached as high as $1.1 million in Q1 2018 and fell as low as $15914.0 in Q4 2016.
• Historically, Non-Current Deffered Revenue has averaged $517522.2 across 3 years, with a median of $278018.0 in 2017.
• Across the five-year window, Non-Current Deffered Revenue jumped 2328.61% in 2017 and declined 11.66% in 2018, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $15914.0 in 2016, then soared by 2328.61% to $386489.0 in 2017, then surged by 170.59% to $1.0 million in 2018.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $1.0 million in Q4 2018, $1.1 million in Q3 2018, and $149785.0 in Q2 2018.